ClinicalTrials.Veeva

Menu
A

Allianz Research Institute | Westminster, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dupilumab
Astegolimab
Bococizumab
EDP-938
Amlitelimab
DUPIXENT®
RPT193
BPS-314d-MR-PAH-303
UPB-101
Verekitug

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 17 total trials

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling
Bronchiectasis
Drug: Placebo
Drug: Itepekimab (SAR440340)

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling
RSV Infection
Drug: Placebo
Drug: EDP-938

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.The purpo...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Amlitelimab

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Trial sponsors

Sanofi logo
Enanta Pharmaceuticals logo
Pfizer logo
Regeneron Pharmaceuticals logo
Genentech logo
Lilly logo
L
RAPT Therapeutics logo
Roche logo
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems